| 19.8 0.43 (2.22%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.03 | 1-year : | 32.74 |
| Resists | First : | 24 | Second : | 28.03 |
| Pivot price | 19.9  |
|||
| Supports | First : | 17.06 | Second : | 12.77 |
| MAs | MA(5) : | 19.5 |
MA(20) : | 18.96 |
| MA(100) : | 16.89 |
MA(250) : | 12.78 |
|
| MACD | MACD : | 0.8  |
Signal : | 0.9 |
| %K %D | K(14,3) : | 37.4 |
D(3) : | 44.1 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 24 | Low : | 7.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MDWD ] has closed above bottom band by 46.3%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.87 - 19.97 | 19.97 - 20.07 |
| Low: | 18.88 - 18.98 | 18.98 - 19.08 |
| Close: | 19.64 - 19.8 | 19.8 - 19.96 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Tue, 23 Jul 2024
Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher - Simply Wall St
Tue, 23 Jul 2024
29,948 Shares in MediWound Ltd. (NASDAQ:MDWD) Purchased by Janney Montgomery Scott LLC - Defense World
Tue, 23 Jul 2024
29,948 Shares in MediWound Ltd. (NASDAQ:MDWD) Acquired by Janney Montgomery Scott LLC - MarketBeat
Tue, 16 Jul 2024
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program - StockTitan
Sun, 07 Jul 2024
MediWound jumps on reports of $400m bid by Solventum - Globes
Sat, 01 Jun 2024
Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 26.2 (%) |
| Held by Institutions | 32 (%) |
| Shares Short | 267 (K) |
| Shares Short P.Month | 248 (K) |
| EPS | -1.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.5 |
| Profit Margin | -64.3 % |
| Operating Margin | -75.3 % |
| Return on Assets (ttm) | -14.2 % |
| Return on Equity (ttm) | -45.2 % |
| Qtrly Rev. Growth | 30.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.13 |
| EBITDA (p.s.) | -1.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -14.56 |
| PEG Ratio | -0.1 |
| Price to Book value | 7.88 |
| Price to Sales | 9.25 |
| Price to Cash Flow | -11.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|